Active Ingredient (In Each Immediate-Release Tablet)
Guaifenesin 200 mg
The following Structured Product Label (SPL) was submitted to the FDA by Major Pharmaceuticals for the product Guaifenesin (NDC 0904-5154). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient (in each immediate-release tablet), purpose, uses, ask a doctor before use if you have, stop use and ask a doctor if, if pregnant or breast-feeding,, keep out of reach of children., directions, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Guaifenesin 200 mg
Expectorant
helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache. These could be signs of a serious illness.
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away.
| adults and children 12 years of age and over | 1 to 2 tablets every 4 hours |
| children 6 to under 12 years of age | ½ to 1 tablet every |
| children under 6 years of age | consult a physician |
FD&C red #40 aluminum lake, magnesium stearate, maltodextrin, microcrystalline cellulose, povidone, silica gel, sodium starch glycolate, stearic acid
NDC 0904-5154-60
MAJOR®
GUAIFENESIN
TABLETS
Guaifenesin 200 mg
Expectorant
100Tablets
Immediate Release
50844 REV0812B58812
Distributed by MAJOR® PHARMACEUTICALS
31778 Enterprise Drive, Livonia, MI 48150 USA
Re-Order No. 238163 M-17 Rev. 04/13
TAMPER EVIDENT: DO NOT USE IF IMPRINTED
SAFETY SEAL UNDER CAP IS BROKEN OR MISSING
* Please review the disclaimer below.